FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906310266> ?p ?o ?g. }

• W2906310266 endingPage "98" @default.
• W2906310266 startingPage "93" @default.
• W2906310266 abstract "Adiponectin is accepted as playing pivotal roles in the development of allergic rhinitis (AR) through modulation of production of inflammatory mediators. Although it is also well known that neuropeptides, especially substance P (SP), function in the development and persistence of clinical conditions of AR, the influence of adiponectin on neuropeptide production is not well understood. The present study was designed to examine the influence of adiponectin on the production of SP both in vivo and in vitro.PC-12 cells (1×104 cells) were stimulated with 10.0 ng/ml nerve growth factor (NGF) for 2 h and then with 10.0 ng/ml capsaicin in the presence of different concentrations of adiponectin. After 72 h, culture supernatants were obtained, and SP levels were measured with enzyme-linked immunosorbent assay (ELISA). The influence of adiponectin on the total number of neurites developed per PC-12 cell and on the percentage of PC-12 cells with outgrowing neurites was also examined 24 and 72 h after the start of culture, respectively. In the second part of the study, BALB/c mice were sensitized intraperitoneally with 1.0 μg of ovalbumin and then challenged with intranasal ovalbumin. At 7 days following sensitization, these mice were treated with different doses of adiponectin intranasally in a volume of 5.0 μl. Nasal allergy-like symptoms, which were induced by bilateral application of 0.1 % OVA (5.0 μl), were assessed by counting sneezing and nasal rubbing behavior for 10 min immediately after nasal ovalbumin challenge. SP levels in nasal lavage fluid obtained 6 h after nasal ovalbumin challenge were examined by ELISA.Treatment of NGF-stimulated PC-12 cells with adiponectin suppressed SP production, which was induced by capsaicin stimulation. The minimum concentration of adiponectin that caused significant suppression was 7.5 ng/ml. On the other hand, adiponectin did not affect the total number of neurites and the percentage of PC-12 cells with outgrowing neurites, even at 1,000 ng/ml. Intranasal instillation of adiponectin into ovalbumin-sensitized mice at more than 10.0 ng/ml, but not 5.0 ng/ml, significantly inhibited the appearance of SP in nasal secretions, which was increased by intranasal challenge with ovalbumin. Adiponectin also suppressed the development of nasal allergic-like symptoms, sneezing and rubbing behavior, when ovalbumin-sensitized mice were treated intranasally with adiponectin at more than 10.0 ng/ml. The present results strongly suggested that adiponectin suppresses the production of SP and results in improvement of the clinical conditions of AR." @default.
• W2906310266 created "2019-01-01" @default.
• W2906310266 creator A5019086225 @default.
• W2906310266 creator A5072138782 @default.
• W2906310266 creator A5076216080 @default.
• W2906310266 date "2018-12-26" @default.
• W2906310266 modified "2023-10-16" @default.
• W2906310266 title "Suppressive Activity of Adiponectin on the Development of Allergic Rhinitis in Mice" @default.
• W2906310266 cites W1887161204 @default.
• W2906310266 cites W1971211949 @default.
• W2906310266 cites W1979898232 @default.
• W2906310266 cites W1994783575 @default.
• W2906310266 cites W1997919403 @default.
• W2906310266 cites W2006113388 @default.
• W2906310266 cites W2016738243 @default.
• W2906310266 cites W2029061945 @default.
• W2906310266 cites W2035483254 @default.
• W2906310266 cites W2038897604 @default.
• W2906310266 cites W2042407953 @default.
• W2906310266 cites W2053321569 @default.
• W2906310266 cites W2063888661 @default.
• W2906310266 cites W2066888686 @default.
• W2906310266 cites W2073412359 @default.
• W2906310266 cites W2074950568 @default.
• W2906310266 cites W2076861829 @default.
• W2906310266 cites W2105691877 @default.
• W2906310266 cites W2158079900 @default.
• W2906310266 cites W2169610547 @default.
• W2906310266 cites W2238272587 @default.
• W2906310266 cites W2358127936 @default.
• W2906310266 cites W2403349595 @default.
• W2906310266 doi "https://doi.org/10.21873/invivo.11444" @default.
• W2906310266 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6364057" @default.
• W2906310266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30587608" @default.
• W2906310266 hasPublicationYear "2018" @default.
• W2906310266 type Work @default.
• W2906310266 sameAs 2906310266 @default.
• W2906310266 citedByCount "3" @default.
• W2906310266 countsByYear W29063102662022 @default.
• W2906310266 countsByYear W29063102662023 @default.
• W2906310266 crossrefType "journal-article" @default.
• W2906310266 hasAuthorship W2906310266A5019086225 @default.
• W2906310266 hasAuthorship W2906310266A5072138782 @default.
• W2906310266 hasAuthorship W2906310266A5076216080 @default.
• W2906310266 hasBestOaLocation W29063102661 @default.
• W2906310266 hasConcept C118303440 @default.
• W2906310266 hasConcept C126322002 @default.
• W2906310266 hasConcept C134018914 @default.
• W2906310266 hasConcept C150903083 @default.
• W2906310266 hasConcept C170493617 @default.
• W2906310266 hasConcept C185592680 @default.
• W2906310266 hasConcept C203014093 @default.
• W2906310266 hasConcept C207001950 @default.
• W2906310266 hasConcept C207480886 @default.
• W2906310266 hasConcept C2776217527 @default.
• W2906310266 hasConcept C2776533618 @default.
• W2906310266 hasConcept C2776782570 @default.
• W2906310266 hasConcept C2776946954 @default.
• W2906310266 hasConcept C2777391703 @default.
• W2906310266 hasConcept C2778423431 @default.
• W2906310266 hasConcept C2779306644 @default.
• W2906310266 hasConcept C71924100 @default.
• W2906310266 hasConcept C85663871 @default.
• W2906310266 hasConcept C86803240 @default.
• W2906310266 hasConcept C8891405 @default.
• W2906310266 hasConceptScore W2906310266C118303440 @default.
• W2906310266 hasConceptScore W2906310266C126322002 @default.
• W2906310266 hasConceptScore W2906310266C134018914 @default.
• W2906310266 hasConceptScore W2906310266C150903083 @default.
• W2906310266 hasConceptScore W2906310266C170493617 @default.
• W2906310266 hasConceptScore W2906310266C185592680 @default.
• W2906310266 hasConceptScore W2906310266C203014093 @default.
• W2906310266 hasConceptScore W2906310266C207001950 @default.
• W2906310266 hasConceptScore W2906310266C207480886 @default.
• W2906310266 hasConceptScore W2906310266C2776217527 @default.
• W2906310266 hasConceptScore W2906310266C2776533618 @default.
• W2906310266 hasConceptScore W2906310266C2776782570 @default.
• W2906310266 hasConceptScore W2906310266C2776946954 @default.
• W2906310266 hasConceptScore W2906310266C2777391703 @default.
• W2906310266 hasConceptScore W2906310266C2778423431 @default.
• W2906310266 hasConceptScore W2906310266C2779306644 @default.
• W2906310266 hasConceptScore W2906310266C71924100 @default.
• W2906310266 hasConceptScore W2906310266C85663871 @default.
• W2906310266 hasConceptScore W2906310266C86803240 @default.
• W2906310266 hasConceptScore W2906310266C8891405 @default.
• W2906310266 hasIssue "1" @default.
• W2906310266 hasLocation W29063102661 @default.
• W2906310266 hasLocation W29063102662 @default.
• W2906310266 hasLocation W29063102663 @default.
• W2906310266 hasLocation W29063102664 @default.
• W2906310266 hasOpenAccess W2906310266 @default.
• W2906310266 hasPrimaryLocation W29063102661 @default.
• W2906310266 hasRelatedWork W156771084 @default.
• W2906310266 hasRelatedWork W1966638871 @default.
• W2906310266 hasRelatedWork W2052337550 @default.
• W2906310266 hasRelatedWork W2061765016 @default.
• W2906310266 hasRelatedWork W2065950538 @default.
• W2906310266 hasRelatedWork W2069971199 @default.

• next